Truist raised the firm’s price target on Corcept Therapeutics to $42 from $36 and keeps a Buy rating on the shares. The company maintained its 2024 Korlym guidance of $600M-$630M despite the recent generic launch by Teva (TEVA), the analyst tells investors in a research note. Korlym and next-gen product candidate relacorilant have significant sales potential for Cushing’s syndrome, and the firm sees the franchise driving solid revenue growth and margin expansion over the next several years, Truist added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CORT:
- Corcept Therapeutics Reports Latest Quarterly Results and Update
- Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
- Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
- CORT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call